http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-603044-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4418 |
| filingDate | 2011-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29295951d3b590f09dcc67be938bd752 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d7b811e5667f3e94c98c663834b9988 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ff086307135be23fa42bb1ffd3cebc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93be6ffb59dd1fb47556d6ac6a63a21f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08634d12b386241c14ce597bff3e93c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0f8c20431d8ea6c6cc8695d4126f2d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef715208a4772c594771288afa153349 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1130b03ba5cf739b5d6f51c71da84e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f196a0fd2543a6b5a004a0c6b72c50c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b72c83bd3f4d1bf35339090b54b1665 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69edbd238a079484c24f64d5243f39f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f94a108c9a5c06875458adcc7ffcd5ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4739a873aaaf5baa7a6e4adbd0615840 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2a4afe2a558011114c128e5361c1007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c95e01937114cf17c6489b4295187ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e71976a212409379282315744a22adf7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bb6997d1e068ff4834938890bed286c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46aab02d81f49c36e29858aa0de6f817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce36db5ddba1bc5518bf5e5356b12e11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7688c2ad83add9a1ea9ce2fd22f77fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e28ce30841cda791b79e403ffa3a5ea9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_304dc198c303bfa910395827f19ecea7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adb82840d539f2da9bb9fdd99181edb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e416749a6b921974e5e5afa40fa4356 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fa2d00ffe86493a5145e4b272ca8496 |
| publicationDate | 2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-603044-A |
| titleOfInvention | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| abstract | Disclosed is a pharmaceutical composition comprising one of the following combinations: a) Compound 1 and Compound 2 Form I; b) Compound 1 Form A and Compound 2 Form I; c) Compound 1 Form A and Compound 2 Tablet Formulation; d) Compound 1 Form A-HCl and Compound 2 Form I; e) Compound 1 Form B-HCl and Compound 2 Form I; f) Compound 1 Form B, and Compound 2 Form I; g) Compound 1 Form A-HCl and Compound 2 Tablet Formulation; h) Compound 1 Form B-HCl and Compound 2 Tablet Formulation; and i) Compound 1 Form B, and Compound 2 Tablet Formulation, wherein Compound 1 is N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide; Compound 2 is lumacaftor (VX-809 / 3-{ 6-{ [1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino} -3-methylpyridin-2-yl} benzoic acid); Compound 1 Form A is characterized by a peak at about 7.9 degrees and a peak at about 11.9 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation; Compound 1 Form A-HCl is characterized by a peak at about 7.1 degrees, a peak at about 8.2 degrees, a peak at about 14.1 degrees, and a peak at about 21.2 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation; Compound 1 Form B-HCl is characterized by a peak at about 8.3 degrees, a peak at about 9.0 degrees, a peak at about 13.0 degrees, a peak at about 18.0 degrees, and a peak at about 23.0 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation; Compound 1 Form B is characterized by a peak at about 6.7 degrees, a peak at about 10.0 degrees, a peak at about 11.2 degrees, a peak at about 13.4 degrees, a peak at about 24.2 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation; Compound 2 Form I is characterized by the following peaks in an X-ray powder diffraction obtained using Cu K alpha radiation: a peak at 15.4 degrees, a peak at 16.3 degrees, and a peak at 14.5 degrees; and Compound 2 Tablet Formulation comprises: a. Compound 2 Form I in an amount ranging from about 20 wt% to about 80 wt% by weight of the composition; b. a filler comprising microcrystalline cellulose in an amount ranging from about 20 wt% to about 50 wt% by weight of the composition; c. a disintegrant comprising sodium croscarmellose sodium in an amount ranging from about 1 wt% to about 5 wt% by weight of the composition; d. a surfactant comprising sodium lauryl sulfate in an amount ranging from about 2 wt% to about 0.3 wt% by weight of the composition; e. a diluent comprising mannitol in an amount ranging from about 1 wt% to about 30 wt% by weight of the composition; f. a lubricant comprising magnesium stearate in an amount ranging from about 0.3 wt% to about 5 wt% by weight of the composition; and g. at least one of: a binder comprising polyvinylpyrrolidone in an amount ranging from about 0.1 wt% to about 5 wt% by weight of the composition and a glidant comprising colloidal silica in an amount ranging from about 0.05 wt% to about 2 wt% by weight of the composition, or Compound 2 Tablet Formulation comprises: a. about 30 wt% of Compound 2 Form I by weight of the composition; b. about 42 wt% of microcrystalline cellulose by weight of the composition; c. about 21 wt% of mannitol by weight of the composition; d. about 3 wt% of sodium croscarmellose sodium by weight of the composition; e. about 1 wt% of sodium lauryl sulfate by weight of the composition; f. about 2.5 wt% of magnesium stearate by weight of the composition; and g. about 0.5 wt% of colloidal silica by weight of the composition; wherein the composition is intended for use in treating a CFTR mediated disease in a human, wherein the CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick’s disease, several polyglutamine neurological disorders such as Huntington’s, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren’s disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham’s Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter’s syndrome type III, Dent’s disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia. |
| priorityDate | 2010-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 227.